Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities

Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have been shown to have unprecedented efficacy in B cell malignancies, most notably in B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate using anti-CD19 CAR-T cells. However, CAR T-cell therapy for so...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Xia, An-Liang, Wang, Xiao-Chen, Lu, Yi-Jun, Lu, Xiao-Jie, Sun, Beicheng
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2017
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685771/
https://ncbi.nlm.nih.gov/pubmed/29163850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19361
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller